BNET Industries
Market Cap:$3.9B
Last Fiscal Year Sales:$2.5B
- Public
- US
Dow Jones Description
Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).
Number of Employees 5,070
Contact Information
311 Bonnie Cir
PO Box 1900
Corona, California 92880
(951) 270-1400
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Trubion CEO out in management shuffle
-
Week of Nov. 16, 2009: GSK and Nabi Form Nicotine Vaccine Agreement; Eli Lilly Research...
-
Watson Pharmaceuticals: Income Statement Analysis for the September 2009 Quarter
-
Watson Pharmaceuticals names new senior vice president and CFO
-
UPDATE 1-Watson names R. Todd Joyce as new CFO
-
CFOs on the Move: Week Ending Nov. 6
-
Week of Nov. 2, 2009: Eli Lilly Opens Biotech Center; Johnson & Johnson Announces Restructuring;...
News & Analysis
Filter by
earnings and watson pharmaceuticals inc. - All News and Analysis
Watson Pharmaceuticals Q3 2009 Earnings Call Transcript
Question-and-Answer SessionOperator (Operator's Instructions) Our first question comes from the line of Tim Chiang with FTN Equity. Tim Chiang - FTN Equity Thanks, Paul. Good morning. I wanted to ask you about the metoprolol launch. How has that gone? Did you have significant revenues...
Watson Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
Question-and-Answer SessionOperator Operator instructions Your first question comes from Randall Stanicky from Goldman Sachs. Bob - Goldman Sachs Hi, good morning guys. This is actually Bob [ph] on for Randall this morning. Paul just quickly on the guidance, I guess could you may be help us understand, what gives...
Watson Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
Earnings Call ExcerptWatson Pharmaceuticals, Inc. WPI Q1 2009 Earnings Call April 30, 2009 08:30 am ET Executives Patty Eisenhaur - Executive Director IR Paul Bisaro - President and CEO Mark Durand - CFO David Buchen - General Counsel Analysts Marc Goodman - UBS Greg Gilbert - Banc of America...
Watson Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Operator instructions We’ll pause for just a moment to compile the Q&A roster. Your question comes from Greg Gilbert with Bank of America. Paul Bisaro Hey, Greg. Greg Gilbert – Bank of America Hey, thanks. Good morning. Paul, you slipped in a comment about pricing improving, given...
Watson Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
Question-and-Answer Session Operator Yes, Ma’am. [Operator instructions] Your first question comes from the line of Tim Chang with FTN Midwest Reasearch. Tim Chang I just wanted to get an update on the generic pipeline, I think you just sort of mentioned one of the key products in that...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Watson Pharmaceuticals
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
